Nyra Medical, an Atlanta, GA-based medical device company developing novel transcatheter mitral valve repair technology, raised $20M in Series A funding.
The round was led co-led by Vensana Capital and a global medical device company, with participation from Broadview Ventures, Epidarex Capital, and the Georgia Research Alliance Venture Fund. In conjunction with this new round of financing, Nyra has added Lisa Wipperman Heine to its board of directors as an independent director.
The company intends to use the funds to advance its technology through early feasibility clinical studies.
Founded by Murali Padala, Nyra Medical is a medical device company developing the CARLEN technology, a transcatheter technology for the treatment of mitral regurgitation. CARLEN preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options.